• Crohn’s disease
• burden
• costs
• inflammatory bowel disease
• quality of life
• ulcerative colitis
• work impairment

• CD
• MYD88
• OTUD4
• SPARC
• intestinal barrier

• Animals
• Crohn Disease/metabolism
• Crohn Disease/genetics
• Mice
• Myeloid Differentiation Factor 88/metabolism
• Myeloid Differentiation Factor 88/genetics
• Humans
• Disease Models, Animal
• Signal Transduction
• Osteonectin/metabolism
• Osteonectin/genetics
• Intestinal Mucosa/metabolism
• NF-kappa B/metabolism
• NF-kappa B/genetics
• Mice, Inbred C57BL
• Male
• Female
• Endopeptidases/metabolism
• Endopeptidases/genetics

• ZDXK202246 Key Laboratory of Jiangsu Province for Chemical Pollution Control and Resources Reuse
• 82300595 National Natural Science Foundation of China
• 82270561 National Natural Science Foundation of China
• 82073156 National Natural Science Foundation of China

• Crohn’s disease
• epidemiology
• inflammatory bowel disease
• real-world
• study
• ulcerative colitis

• Takeda Mexico, S.A. de C.V.

• clinical remission
• deep remission
• endoscopic remission
• histologic remission
• new therapeutic targets
• transmural remission

• CEUS in abdomen and pelvis
• CEUS in trauma and pediatric population and intervensions
• CEUS of the liver and renal masses

• Humans
• Contrast Media
• Ultrasonography/methods
• Child
• Adult
• Microbubbles

• Humans
• Drug Development/methods
• Inflammatory Bowel Diseases/drug therapy
• Inflammatory Bowel Diseases/immunology
• Clinical Trials as Topic
• Animals
• Machine Learning
• Biomarkers/metabolism
• Colitis, Ulcerative/drug therapy
• Colitis, Ulcerative/immunology
• Crohn Disease/drug therapy

• Crohn’s disease
• Endoscopic remission
• Inflammatory bowel disease
• Intestinal ultrasound
• Time to response
• Transmural healing
• Treat to target
• Treatment targets

• Humans
• Crohn Disease/therapy
• Crohn Disease/drug therapy
• Remission Induction
• Inflammatory Bowel Diseases/therapy
• Ultrasonography

• Crohn's disease
• Perianal fistula
• Surface enhanced Raman spectroscopy
• Urine

• Humans
• Crohn Disease/complications
• Crohn Disease/diagnosis
• Crohn Disease/therapy
• Spectrum Analysis, Raman
• Rectal Fistula/diagnosis
• Rectal Fistula/etiology
• Prognosis
• Anus Diseases/complications
• Cutaneous Fistula
• Treatment Outcome

• BANF1
• Crohn’s disease
• Intestinal epithelial barrier
• NF-κB pathway
• TMIGD1

• Animals
• Mice
• Colitis/chemically induced
• Colitis/drug therapy
• Colitis/pathology
• Crohn Disease/genetics
• Cytokines/metabolism
• Inflammation/metabolism
• Intestinal Mucosa/metabolism
• Intestinal Mucosa/pathology
• NF-kappa B/metabolism
• NF-kappa B/therapeutic use
• Tumor Necrosis Factor Inhibitors/adverse effects
• Tumor Necrosis Factor Inhibitors/metabolism

• National Natural Science Foundation of China

• Crohn’s disease
• Inflammatory Bowel Disease
• Janus kinase inhibitors
• Tyk2 inhibitors
• ulcerative colitis

• Adult
• Humans
• Colitis, Ulcerative/drug therapy
• Janus Kinase Inhibitors/therapeutic use
• Crohn Disease/drug therapy
• Inflammatory Bowel Diseases/drug therapy
• Inflammatory Bowel Diseases/complications
• Europe

• Humans
• Crohn Disease/diagnosis
• Remission Induction
• Antibodies, Monoclonal

• Crohn’s disease
• disease activity
• mucosal healing

• Crohn’s disease
• IBD
• Inflammatory bowel disease
• cannabis
• marijuana
• review
• ulcerative colitis

• Crohn Disease/diagnosis
• Discriminant Analysis
• Humans
• Principal Component Analysis
• Spectrum Analysis, Raman
• Support Vector Machine

Aim: This study aimed to evaluate the clinical significance of fecal calprotectin (FC) in assessment of ulcerative colitis (UC) patients' endoscopic patterns and clinical manifestation.

Methods: A total of 143 UC patients who received colonoscopy and 108 controls were included. After providing stool samples, patients underwent total colonoscopy. FC was measured by an enzyme-linked immunosorbent assay (ELISA). Clinical activity was based on the Mayo score. Endoscopic findings was scored by the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Correlation analysis and receiver-operator characteristic (ROC) analysis were carried out to determine the significance of measurements.

Results: The median (interquartile range, IQR) of FC levels was 211 (43–990) μg/g in UC and 87.5 (40.50~181) μg/g in the control group. Fecal calprotectin correlated significantly with both Mayo and UCEIS scores (Spearman's r 0.670 and 0.592, P < 0.01). With a cut-off value of 164 μg/g for fecal calprotectin concentration, the area under the curve (AUC) in receiver operator characteristic analysis was 0.830, sensitivity was 85.42%, specificity was 73.68%, positive predictive value (PPV) was 62.12%, and negative predictive value (NPV) was 9.10% in predicting clinical active disease. Similarly, the power of FC to predict mucosal healing (MH) was modest. With a cut-off value of 154.5 μg/g, the AUC was 0.839, sensitivity was 72.34%, and specificity was 85.71%.

Conclusion: For evaluating the disease activity of UC, FC is a clinically relevant biomarker for both clinically active disease and MH in patients with UC. But the cut-off value still needs large and multicenter studies for confirmation.

• biomarkers
• clinical value
• fecal calprotectin
• mucosal healing
• ulcerative colitis

• Crohn disease
• controlled radial expansion
• double-balloon endoscopy
• endoscopic balloon dilation
• inflammatory bowel disease
• small bowel

• chronic illness
• inflammatory bowel disease
• irritable bowel syndrome
• psychogastroenterology

• University of Minnesota Medical School, Department of Medicine, Division of General Internal Medicine Pilot Grant Program

Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBDs) with a remission-relapsing presentation and symptomatic exacerbations that have detrimental impacts on patient quality of life and are associated with a high cost burden, especially in patients with moderate-to-severe disease. The Real-world Data of Moderate-to-Severe Inflammatory Bowel Disease in Brazil (RISE BR) study was a noninterventional study designed to evaluate disease control, treatment patterns, disease burden and health-related quality of life in patients with moderate-to-severe active IBD. We report findings from the prospective follow-up phase of the RISE BR study in patients with active UC or CD.

To describe the 12-mo disease evolution and treatment patterns among patients with active moderate-to-severe IBD in Brazil.

This was a prospective, noninterventional study of adult patients with active Crohn’s disease (CD: Harvey-Bradshaw Index ≥ 8, CD Activity Index ≥ 220), inadequate CD control (i.e., calprotectin > 200 µg/g or colonoscopy previous results), or active ulcerative colitis (UC: Partial Mayo score ≥ 5). Enrollment occurred in 14 centers from October 2016 to February 2017. The proportion of active IBD patients after 9-12 mo of follow-up, Kaplan-Meier estimates of the time to mild or no activity and a summary of treatment initiation, discontinuation and dose changes were examined.

The study included 118 CD and 36 UC patients, with mean ± SD ages of 43.3 ± 12.6 and 44.9 ± 16.5 years, respectively. The most frequent drug classes at index were biologics for CD (62.7%) and 5-aminosalicylate derivates for UC patients (91.7%). During follow-up, 65.3% of CD and 86.1% of UC patients initiated a new treatment at least once. Discontinuations/dose changes occurred in 68.1% of CD patients [median 2.0 (IQR: 2-5)] and 94.3% of UC patients [median 4.0 (IQR: 3-7)]. On average, CD and UC patients had 4.4 ± 2.6 and 5.0 ± 3.3 outpatient visits, respectively. The median time to first mild or no activity was 319 (IQR: 239-358) d for CD and 320 (IQR: 288-358) d for UC patients. At 9-12 mo, 22.0% of CD and 20.0% of UC patients had active disease.

Although a marked proportion of active IBD patients achieved disease control within one year, the considerable time to achieve this outcome represents an unmet medical need of the current standard of care in a Brazilian real-world setting.

• Crohn’s disease
• Ulcerative colitis
• Inflammatory bowel diseases
• Prospective study

• Adult
• Brazil/epidemiology
• Colitis, Ulcerative/diagnosis
• Colitis, Ulcerative/drug therapy
• Colitis, Ulcerative/epidemiology
• Humans
• Inflammatory Bowel Diseases
• Middle Aged
• Prospective Studies
• Quality of Life

• fecal calprotectin
• inflammatory bowel disease
• irritable bowel syndrome
• crohn’s disease
• ulcerative colitis
• stool

• Biomarkers
• Colitis, Ulcerative/diagnosis
• Cross-Sectional Studies
• Feces
• Female
• Humans
• Inflammatory Bowel Diseases/diagnosis
• Irritable Bowel Syndrome/diagnosis
• Leukocyte L1 Antigen Complex
• Male

• Faecalibacterium prausnitzii
• T helper 17 cells
• histone deacetylase
• inflammatory bowel disease
• metabolism

• Crohn’s disease
• Gut dysmotility
• Inflammatory bowel disease
• Ulcerative colitis

• Ultrasound
• diagnostic accuracy
• monitoring
• paediatric inflammatory bowel disease

Inflammatory bowel diseases (IBD) have been associated with a low quality of life (QoL) and a negative impact on work productivity compared to the general population. Information about disease control, patient-reported outcomes (PROs), treatment patterns and use of healthcare resources is relevant to optimizing IBD management.

To describe QoL and work productivity and activity impairment (WPAI), treatment patterns and use of healthcare resources among IBD patients in Brazil.

A multicenter cross-sectional study included adult outpatients who were previously diagnosed with moderate to severe Crohn’s disease (CD) or ulcerative colitis (UC). At enrolment, active CD and UC were defined as having a Harvey Bradshaw Index ≥ 8 or a CD Activity Index ≥ 220 or calprotectin > 200 µg/g or previous colonoscopy results suggestive of inadequate control (per investigator criteria) and a 9-point partial Mayo score ≥ 5, respectively. The PRO assessment included the QoL questionnaires SF-36 and EQ-5D-5L, the Inflammatory Bowel Disease Questionnaire (IBDQ), and the WPAI questionnaire. Information about healthcare resources and treatment during the previous 3 years was collected from medical records. Chi-square, Fisher’s exact and Student’s t-/Mann-Whitney U tests were used to compare PROs, treatment patterns and the use of healthcare resources by disease activity (α = 0.05).

Of the 407 patients in this study (CD/UC: 64.9%/35.1%, mean age 42.9/45.9 years, 54.2%/56.6% female, 38.3%/37.1% employed), 44.7%/25.2% presented moderate-to-severe CD/UC activity, respectively, at baseline. Expressed in median values for CD/UC, respectively, the SF-36 physical component was 46.6/44.7 and the mental component was 45.2/44.2, the EQ-visual analog scale score was 80.0/70.0, and the IBDQ overall score was 164.0/165.0. Moderate to severe activity, female gender, being unemployed, a lower educational level and lower income were associated with lower QoL (P < 0.05). Median work productivity impairment was 20% and 5% for CD and UC patients, respectively, and activity impairment was 30%, the latter being higher among patients with moderate to severe disease activity compared to patients with mild or no disease activity (75.0% vs 10.0%, P < 0.001). For CD/UC patients, respectively, 25.4%/2.8% had at least one surgery, 38.3%/19.6% were hospitalized, and 70.7%/77.6% changed IBD treatment at least once during the last 3 years. The most common treatments at baseline were biologics (75.3%) and immunosuppressants (70.9%) for CD patients and 5-ASA compounds (77.5%) for UC patients.

Moderate to severe IBD activity, especially among CD patients, is associated with a substantial impact on QoL, work productivity impairment and an increased number of IBD surgeries and hospitalizations in Brazil.

• Inflammatory bowel disease
• Crohn’s disease
• Ulcerative colitis
• Quality of life
• Healthcare resources

• Adult
• Brazil/epidemiology
• Colitis, Ulcerative/complications
• Colitis, Ulcerative/diagnosis
• Colitis, Ulcerative/epidemiology
• Colitis, Ulcerative/surgery
• Crohn Disease/complications
• Crohn Disease/diagnosis
• Crohn Disease/epidemiology
• Crohn Disease/surgery
• Cross-Sectional Studies
• Employment/statistics & numerical data
• Facilities and Services Utilization/statistics & numerical data
• Female
• Hospitalization/statistics & numerical data
• Humans
• Male
• Middle Aged
• Patient Acceptance of Health Care/statistics & numerical data
• Patient Reported Outcome Measures
• Prospective Studies
• Quality of Life
• Severity of Illness Index

• Dialectical behavior therapy
• Irritable bowel syndrome
• Mindfulness based cognitive therapy
• Perceived stress
• Positive psychotherapy
• Quality of life

• Biomarker
• C-reactive protein
• Crohn’s disease
• endoscopy
• fecal calprotectin
• mucosal healing
• treat-to-target

• Biomarker
• C-reactive protein
• Crohn's disease
• Fecal calprotectin
• Monitoring

Inflammatory bowel disease (IBD) as a chronic and debilitating disease is affected by sleep disturbance which increases the risk of malignancy. Sleep disturbance is more common in irritable bowel syndrome (IBS) and few reported studies have assessed its role in IBD. We evaluated the effect of IBS on sleep quality and quality of life (QOL) of IBD patients in clinical remission.

In a cross-sectional study, 115 IBD patients in clinical remission aged from 14 to 70 years referred to gastroenterology outpatient departments and private gastroenterology offices from 2007 to 2016. Patients considered in four groups (with/without IBS). The Revised “Rome III criteria” used for diagnosing IBS. Pittsburgh Sleep Quality Index questionnaire and the health-related QOL questionnaire used for evaluating sleep quality and QOL.

About 85 (73.9%) cases had ulcerative colitis (UC) and 30 (26.1%) cases had Crohn's disease (CD). Forty (34.8%) cases had IBD + IBS. Poor sleep quality in UC + IBS (OR: 0.018, P = 0.003) and UC (OR: 0.016, P = 0.002) was less than CD. Diseases extent in left side colitis (OR: 0.064, P = 0.016) were less than with pancolitis. Sleep quality affected by quality of life (IBDQ) (P = 0.048). Mean quality of life (IBDQ) in patients who had poor sleep was 11% less than those with good sleep.

The syndrome of IBS affects the sleep quality of IBD in clinical remission, especially in CD. Its additive effect with IBD may worsen symptoms that correlated with sleep disturbance, such as pain, psychological and physical condition, and QOL.

• Inflammatory bowel diseases
• irritable bowel syndrome
• quality of life
• sleep

• Adult
• Carbon Isotopes/analysis
• Case-Control Studies
• Crohn Disease/diet therapy
• Dietary Supplements
• Energy Intake
• Female
• Food, Formulated
• Hair/chemistry
• Humans
• Lipids/pharmacokinetics
• Male
• Mass Spectrometry/methods
• Nitrogen Isotopes/analysis
• Nutrition Assessment
• Scalp
• Selenium/analysis

• celiac disease
• clinical trials
• gluten
• gluten free diet

• Celiac Disease/therapy
• Clinical Trials as Topic
• Humans
• Outcome Assessment, Health Care
• Patient Preference
• Quality of Life

• Competitive Research Funding of the Tampere University Hospital
• Leibniz Foundation
• Ministry of Research and Development (BMBF), Germany
• Svenska Läkaresällskapet
• Hungarian Research Fund
• Deutsche Forschungsgemeinschaft
• Vetenskapsrådet
• itive State Research Financing of the Tampere University
• Suomen Akatemia
• The Sigrid Juselius Foundation

• Adult
• Crohn Disease/diagnostic imaging
• Crohn Disease/surgery
• Endoscopy, Gastrointestinal
• Female
• Humans
• Logistic Models
• Male
• Middle Aged
• Predictive Value of Tests
• Proportional Hazards Models
• Prospective Studies
• ROC Curve
• Risk Assessment
• Risk Factors
• Severity of Illness Index
• Tertiary Care Centers
• Ultrasonography
• Young Adult

• CDAI
• biomarkers
• patient-reported outcomes

• CLE
• Intestinal Barrier Function
• Leaky Gut
• Small Intestine

• Crohn's disease
• Therapy
• Treat to target
• Treatment algorithms
• Treatment paradigms

Faecal calprotectin and faecal occult blood test (FOBT) were widely used in the diagnosis and assessment of intestinal inflammation in inflammatory bowel disease (IBD). Recently we identified an excellent new biomarker B cell-activating factor (BAFF) for IBD. Here in this study we compared the efficacy of faecal BAFF, calprotectin and FOBT to find the “best non-invasive marker”. Results showed that for discriminating IBD from IBS, BAFF ≥227.3 pg/ml yield 84% sensitivity, 100% specificity, 100% positive predictive value (PPV) and 64% negative predictive value (NPV) while calprotectin ≥50 µg/g yield 76% sensitivity, 93% specificity, 97% PPV and 53% NPV. FOBT yield 65% sensitivity, 93% specificity, 97% PPV and 43% NPV. Combining BAFF with calprotectin tests yield 94% sensitivity, 93% specificity, 98% PPV, 81% NPV. Faecal BAFF level showed the stronger correlation with endoscopic inflammatory score as compared to calprotectin not only in UC (correlation coefficient [r] = 0.69, p < 0.0001 vs. r = 0.58, p < 0.0001), but also in CD (r = 0.58, p < 0.0001 vs. r = 0.52, p = 0.0003). Our results indicating that faecal BAFF is a promising non-invasive biomarker in IBD differential diagnosis and monitoring of intestinal inflammation.

To investigate the effect of a low-FODMAP diet on irritable bowel syndrome (IBS)-like symptoms in patients with inflammatory bowel disease (IBD).

This was a randomised controlled open-label trial of patients with IBD in remission or with mild-to-moderate disease and coexisting IBS-like symptoms (Rome III) randomly assigned to a Low-FODMAP diet (LFD) or a normal diet (ND) for 6 wk between June 2012 and December 2013. Patients completed the IBS symptom severity system (IBS-SSS) and short IBD quality of life questionnaire (SIBDQ) at weeks 0 and 6. The primary end-point was response rates (at least 50-point reduction) in IBS-SSS at week 6 between groups; secondary end-point was the impact on quality of life.

Eighty-nine patients, 67 (75%) women, median age 40, range 20-70 years were randomised: 44 to LFD group and 45 to ND, from which 78 patients completed the study period and were included in the final analysis (37 LFD and 41 ND). There was a significantly larger proportion of responders in the LFD group (n = 30, 81%) than in the ND group (n = 19, 46%); (OR = 5.30; 95%CI: 1.81-15.55, P < 0.01). At week 6, the LFD group showed a significantly lower median IBS-SSS (median 115; inter-quartile range [IQR] 33-169) than ND group (median 170, IQR 91-288), P = 0.02. Furthermore, the LFD group had a significantly greater increase in SIBDQ (median 60, IQR 51-65) than the ND group (median 50, IQR 39-60), P < 0.01.

In a prospective study, a low-FODMAP diet reduced IBS-like symptoms and increased quality of life in patients with IBD in remission.

• Inflammatory bowel disease
• Web-based management
• Irritable bowel syndrome
• Low-FODMAP diet

• Adult
• Aged
• C-Reactive Protein/metabolism
• Diet
• Disaccharides/chemistry
• Female
• Fermentation
• Humans
• Inflammatory Bowel Diseases/diagnosis
• Inflammatory Bowel Diseases/therapy
• Internet
• Irritable Bowel Syndrome/diagnosis
• Irritable Bowel Syndrome/therapy
• Male
• Middle Aged
• Monosaccharides/chemistry
• Oligosaccharides/chemistry
• Patient Compliance
• Prospective Studies
• Quality of Life
• Remission Induction
• Young Adult

• Crohn’s disease
• clinical trials

• Allopurinol
• Ayurveda
• Boswellia
• Chinese medicine
• Crohn’s disease
• Curcumin
• Inflammatory bowel disease
• Irritable bowel syndrome
• Omega-3 fatty acids
• Ulcerative colitis

• Allopurinol/therapeutic use
• Antioxidants/pharmacology
• Antioxidants/therapeutic use
• Colitis, Ulcerative/drug therapy
• Crohn Disease/drug therapy
• Dietary Supplements
• Fatty Acids, Omega-3/therapeutic use
• Gastrointestinal Microbiome/physiology
• Gastrointestinal Tract/physiopathology
• Humans
• Inflammatory Bowel Diseases/diagnosis
• Inflammatory Bowel Diseases/drug therapy
• Irritable Bowel Syndrome/diagnosis
• Irritable Bowel Syndrome/drug therapy
• Medicine, Traditional/methods
• Plants, Medicinal